viecure

5680 Greenwood Plaza Blyd, Ste 350
Greenwood Village, CO 80111

+1 720-443-5420
info@viecure.com

CY 2024 Real World Testing Report for VieCure

Executive Summary

This is the test report for CY 2024 real world testing for our VieCure certified EHR solution. This is the companion document to our CY 2024 real world test plan that described our approach for conducting real world testing in CY 2024 and the testing measures we employed.

Our findings show that EHR is working in our production as it was certified. For each our CY 2024 Real World Testing Measures, we have recorded our results and findings. We did not discover any non-conformities or errors from our testing.

Our signed attestation of compliance with the real world testing requirements is on the following page.

viecure

Developer Attestation

This Real World Testing report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Signature:

Heath McMillion

DATE 2/20/2025

viecure

General Information

Plan Report ID Number: VieCure-RWT-2024

Developer Name: VieCure, Inc

Product Name(s): VieCure

Version Numbers(s): 3.2

Certified Health IT Criteria: 315(b)(1)-(3), (b)(6), (c)(1), (e)(1), (f)(2), (f)(5), (g)(7)-(9), (h)(1)

Product List (CHPL) ID(s) and Link(s):

- 15.04.04.3066.VieC.03.01.1.210128
- https://chpl.healthit.gov/#/listing/10541

Developer Real World Testing Page URL: https://www.viecure.com/certifications-1

viecure

Timeline and Milestones for Real World Testing CY 2024

- Milestone 1Q-2024: 1Q-2024: Health IT system is fully enabled for use in real world testing.
    - STATUS: MET
- Milestone 3Q 2024. Begin making plans to collect data for RWT measures. If necessary, engage clients to ask for their support and participation in real world testing.
    - STATUS: MET
- Milestone 4Q-2024. During the last quarter of the year, the CY 2024 real world test plan will be completed according to ONC and ONC-ACB requirements and expectations. Test plan will be prepared for submission.
    - STATUS: MET

viecure

Standards Version Advancement Process (SVAP) Updates

For CY 2024 RWT testing, we tested with USCDI v1.

Standard (and version)	All standards versions are those specified in certification criteria.
Date of ONC-ACB notification (SVAP or USCDI)	N/A
Date of customer notification (SVAP only)	N/A
USCDI-updated certification criteria (and USCDI version)	The plan documents the support of all USCDI v1 data elements.

viecure

RWT Measure #1. Transitions of Care

Associated Criteria: 315(b)(1), (h)(1)

Measurement Description

This measure is tracking and counting the number of messages with CCDAs attached successfully sent.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of messages with CCDAs attached successfully sent

Total: 0 for all clinics during dates of Jan-Dec 2024

Changes to Original Plan

Summary of Change: We conducted a simulated test using four different synthetic test patients against the SITE C-CDA validator. The results of all our test patients showed no errors and passed against this C-CDA implementation guide specifications.

Reason: Because of our zero results for this measure, we utilized an alternative test method to verify compliance.

Impact: Low to No Impact. Our modified test measure reveals our functionality is compliant as it would have with our original test measurement.

Analysis and Key Findings

Last year, our users elected to share patient records through an alternative methods of exchange in lieu of C-CDAs and Direct transmission. However, we have tested our C-CDA generation capabilities and validate the file using the C-CDA validation test tool. Also, we confirmed our relied upon software HISP, EMRDirect, is working properly in a production setting. We believe more customers will start using C-CDAs in the near future and continue to encourage their use.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. Because of the low use of this functionality, we supplemented the testing with additional compliance test as described above.

viecure

RWT Measure #2. NewRx Prescriptions

Associated Criteria: 315(b)(3)

Measurement Description

This measure is tracking and counting how many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a given interval. The interval for this measure will be three (3) months

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: Number successfully sent from the EHR Module to a pharmacy destination.

Total eRx: 97,315 for all clinics during dates of all CY 2024

Total Prescriptions: 100,532 for all clinics during dates of all CY 2024

Analysis and Key Findings

Electronic prescribing is a popular feature with our client base, and our results support its widespread use. Approximately 97% of all prescriptions created are submitted electronically. Our results are up over 3% from last year showing steady growth.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #3. Error Rate in Problem/Medication/Allergy Incorporation from C-CDA

Associated Criteria: 315(b)(2)

Measurement Description

This measure metric is the error rate of the EHR Module incorporating problem/medication/allergy from C-CDAs into the respective patient records.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: error rate of medications, allergies and problems incorporated from a received C-CDA

Result: 0%

Testing Metric/Measurement: number of reconciliation of medications, allergies and problems from a received C-CDA

Total: 0 for all clinics during dates of CY 2024

Changes to Original Plan

Summary of Change: We conducted a simulated test using synthetic test patients by incorporating three different C-CDAs and visually confirming the user could incorporate problems, medications, and allergies into the respective lists in the EHR patient record. The results of our test patients showed no errors and met compliance.

Reason: Because of our zero results for this measure, we utilized an alternative test method to verify compliance.

Impact: Low to No Impact. Our modified test measure reveals our functionality is compliant as it would have with our original test measurement.

viecure

Analysis and Key Findings

Our clinicians are typically not receiving C-CDAs from other providers, but additional internal testing and audit results do not indicate any errors or failures with the functionality. We do believe we will start receiving more C-CDAs in the near future as our customer base grows, and we will continue to support this incorporation capability.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. Because of the low use of this functionality, we supplemented the testing with additional compliance test as described above.

viecure

RWT Measure #4. Quality Measure Success Rate

Associated Criteria: 315(c)(1)

Measurement Description

This measure is tracking the measure calculation of patients or episodes of care which meet the numerator criteria of the quality measures certified in the EHR as displayed in our system's CQM dashboard.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: calculation of patients or episodes of care which meet the numerator criteria of the quality measures certified in the EHR as displayed in our system's CQM dashboard for one selected customer site:

Measure	Result
Quality ID #130: Documentation of Current Medications in the Medical Record	99.52%
Quality ID #47: Advance Care Plan	99.95%
Quality ID #131: Pain Assessment and Follow-Up	99.62%
Quality ID #144: Plan of Care for Pain	99.88%
Quality ID #134: Screening for Depression and Follow-Up Plan	99.88%
Quality ID #226: Tobacco Use: Screening and Cessation Intervention	95.75%, 61.38%, 89.9%
Quality ID # 374: Closing Referral Loop	97.18%
Quality ID #226: Alcohol Screening	94.22%, 72%, 93.6%
Quality ID #487: Screening for SDOH	99.75%

viecure

Analysis and Key Findings

Currently, none of our customers are reporting quality measures using our certified eCQM measure calculations. Instead, our clients report quality measures via various registries and other systems for while still relying on our EHR to provide the underlying patient data.

While not part of the ONC certification criteria, these quality measures are still utilized in CMS programs, and our customers rely on the accuracy of our clinical data for their calculations. The result report shows the calculations of these different quality measures from one of our customers an example of how our system is providing functionality for achieving quality measure submission

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. As noted, we made an alteration in our report to included results from non-eCQM quality report to match how our customers are choosing to use our EHR.

viecure

RWT Measure #5. Number of Patients Given Access to Portal

Associated Criteria: 315(e)(1)

Measurement Description

This measure is tracking and counting how many patients are given login access to their patient portal account.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of patients given login access to their patient portal account

Total: 9,136 for all clinics during 2024

Baseline from Last Year's Results: 7,764

Analysis and Key Findings

Our clients began using our patient portal toward the end of last year, and we have seen significant growth of over 15% year over year. Also, we confirmed our relied upon software HISP, EMRDirect, is working properly in a production setting. We expect this number to continue to increase in the following years.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #6. Syndromic Surveillance Error Rate

Associated Criteria: 315(f)(2)

Measurement Description

This measure is recording the error rate in creating syndromic surveillance message.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of syndromic surveillance registries engaged

Total: 0 messages sent for all clinics during 2024

Changes to Original Plan

Summary of Change: We conducted a simulated test using two different synthetic test patients and testing their compliance with the NIST syndromic surveillance test tool. The results of our testing with our synthetic patients showed no errors and demonstrated compliance with the criteria.

Reason: Because of our zero results for this measure, we utilized an alternative test method to verify compliance.

Impact: Moderate Impact. Our modified test measure reveals our message creation functionality is compliant as it would have with our original test measurement, but we could not simulate connecting with an actual registry.

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality in their practices. The functionality is enabled in our production system, but customers have yet to request to be onboarded with a public registry.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. Because of the low use of this functionality, we supplemented the testing with additional compliance test as described above.

viecure

RWT Measure #7. Electronic Case Message Error Rate

Associated Criteria: 315(f)(5)

Measurement Description

This measure is recording the error rate in creating electronic case message.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of electronic case registries engaged

Total: 0 messages sent for all clinics during 2024

Changes to Original Plan

Summary of Change: we conducted a simulated test using four different synthetic test patients against the SITE C-CDA validator generated from an eCR triggering method. The results of all our test patients showed no errors and passed against this C-CDA implementation guide specifications.

Reason: Because of our zero results for this measure, we utilized an alternative test method to verify compliance.

Impact: Moderate Impact. Our modified test measure reveals our message creation functionality is compliant as it would have with our original test measurement, but we could not simulate connecting with an actual registry.

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality in their practices. The functionality is enabled in our production system, but customers have yet to request to be onboarded with a public registry.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. Because of the low use of this functionality, we supplemented the testing with additional compliance test as described above.

viecure

RWT Measure #8. Number of Different Applications/3rd Party Systems Using API Capabilities

Associated Criteria: 315(g)(7), (9)

Measurement Description

This measure is tracking and counting the number of organizations with an active syndromic surveillance registry interface.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of different systems or applications are connecting to the EHR via the API

Total: 0 for all clinics during 2024

Changes to Original Plan

Summary of Change: We conducted a simulated test using two different synthetic test patients. We retrieved them via the Postman API tool using our 315(g)(9) API and then tested them against the SITE C-CDA validator. Both test patients passed validation without errors.

Reason: Because of our zero results for this measure, we utilized an alternative test method to verify compliance.

Impact: Low to No Impact. Our modified test measure reveals our functionality is compliant as it would have with our original test measurement.

Analysis and Key Findings

We did not have any requests to use our certified FHIR API functionality. Our customers are using other non-FHIR API connections for data exchange, but they have yet to onboard a client using FHIR. Using the Postman API tool, we have confirmed the functionality is present in the production setting. Additional internal testing does not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. Because of the low use of this functionality, we supplemented the testing with additional compliance test as described above.